- Description
- 3rd Party Lab Testing
Description
Product Overview
The Reta GLP-3 + CJC-1295 No DAC bundle offers a dual-hormonal research model designed to study metabolic regulation, energy balance, and growth hormone (GH) dynamics.
Retatrutide (Reta-GLP-3) is a triple agonist peptide that activates the GLP-1, GIP, and glucagon receptors, enabling research into metabolic function, blood sugar control, and fat oxidation. CJC-1295 No DAC, a synthetic analog of growth hormone–releasing hormone (GHRH), promotes natural pulsatile GH release and supports studies in cellular regeneration, endocrine signaling, and lean muscle maintenance.
Together, these peptides form a powerful research tool for studying metabolic flexibility, anabolic balance, and hormonal synergy—with applications spanning obesity, energy regulation, anti-aging, and GH/IGF-1 pathway studies.
Technical Specifications
Retatrutide (Reta-GLP-3): 12mg lyophilized peptide vial
CJC-1295 No DAC: 10mg lyophilized peptide vial
Purity: >99% (HPLC-tested)
Form: Lyophilized powder
Storage: Stable at room temperature before reconstitution; refrigerate after reconstitution
Why Choose BioEdge Research Labs Reta GLP-3 + CJC-1295 No DAC?
-
Research Grade Purity: Verified purity >99% by third-party HPLC analysis.
-
Secure Packaging: Designed to maintain peptide stability and prevent degradation during shipment and storage.
-
Fast Shipping: Most orders ship within 24 hours of payment confirmation from our U.S.-based facility.
-
Researcher Support: Expert customer service from experienced peptide specialists.
Summary of Preclinical Research Findings
Metabolic Regulation & Energy Balance
Retatrutide’s incretin and glucagon receptor activity allows research into glucose metabolism, appetite regulation, and fat oxidation. When paired with CJC-1295 No DAC, studies can explore the interaction between incretin-driven metabolic control and GH-mediated energy expenditure.
Growth Hormone & IGF-1 Pathways
CJC-1295 No DAC enhances pulsatile GH secretion, offering an experimental model for studying anabolic signaling and tissue regeneration. Combined with Retatrutide’s effects on insulin sensitivity and lipid metabolism, this stack supports investigation into GH/IGF-1 synergy in fat reduction and muscle preservation.
Fat Metabolism & Body Composition
Researchers can analyze how this dual-pathway stack influences visceral fat, lean muscle mass, and overall metabolic efficiency. Retatrutide supports thermogenesis and caloric balance, while CJC-1295 No DAC promotes GH-driven lipolysis and protein synthesis.
Endocrine and Hormonal Signaling
The combination enables exploration of hormone feedback loops and receptor crosstalk between the hypothalamic-pituitary and incretin systems. It supports research into how short-acting GH pulses complement GLP-1/GIP activity in regulating blood glucose and body composition.
Regeneration & Anti-Aging Studies
CJC-1295 No DAC has been examined in tissue recovery and cellular repair models, while Retatrutide provides complementary insights into metabolic health and oxidative balance. Together, they create a research framework for studying age-related hormonal decline and restorative metabolic responses.
Suggested Research Applications
-
Dual-pathway analysis of metabolic and hormonal regulation
-
Studies of GH and IGF-1 axis in relation to fat metabolism
-
Endocrine signaling and receptor crosstalk models
-
Cellular regeneration and tissue recovery research
-
Energy expenditure and thermogenic pathway evaluation
-
Lean muscle preservation during metabolic alteration
-
Anti-aging and hormone feedback regulation studies
For Research Use Only
The Reta GLP-3 12mg + CJC-1295 No DAC 10mg bundle is supplied by BioEdge Research Labs exclusively for laboratory and in vitro research.
-
Not for human or animal use
-
Not for medical or diagnostic purposes
-
Purchase confirms that the buyer is a qualified researcher aged 18 or older
-
All usage must comply with local laws and laboratory safety standards
Summary of References
Retatrutide in Metabolic Research
-
Jastreboff, A. M., et al. (2023). Triple-hormone receptor agonist Retatrutide supports significant weight loss in obesity models. New England Journal of Medicine, 389(1), 11–22. https://www.nejm.org/doi/abs/10.1056/NEJMoa2301972
-
Wharton, S., et al. (2023). Body weight outcomes in patients receiving Retatrutide: Phase 2 findings. The Lancet, 402(10397), 9–20. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/abstract
-
Lin, Y., et al. (2024). Retatrutide and fat distribution in metabolic obesity models. Nature Medicine, 30(4), 511–520. https://www.nature.com/articles/s41591-024-03018-2
CJC-1295 No DAC in Growth Hormone and Regeneration Research
-
Mieritz, M. G. et al. (2009). Body composition and metabolic outcomes after GH analog administration. Hormone Research in Paediatrics, 72(2), 114–122. https://www.sciencedirect.com/science/article/pii/S1096637409000409
-
Lapira, J. et al. (2008). Age-related GHRH signaling and GH pulsatility. Journal of Neuroendocrinology, 20(9), 1012–1019. https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2826.2008.01740.x
-
Bridon, D. P. et al. (2004). CJC-1295 as a long-acting GHRH analog with regenerative implications. ResearchGate. Link to Study.
BioEdge Research Labs
Precision. Purity. Performance.
At BioEdge, we are committed to providing research professionals with the highest quality peptides on the market. Every compound we supply is manufactured in a cGMP-certified facility, undergoes rigorous third-party testing, and is intended strictly for in vitro or laboratory research use only.
